228 related articles for article (PubMed ID: 29630889)
1. Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort.
Pinsky PF; Miller E; Heckman-Stoddard B; Minasian L
Am J Obstet Gynecol; 2018 Jun; 218(6):606.e1-606.e9. PubMed ID: 29630889
[TBL] [Abstract][Full Text] [Related]
2. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer.
Anderson C; Nichols HB; House M; Sandler DP
Cancer Prev Res (Phila); 2019 Nov; 12(11):801-808. PubMed ID: 31431499
[TBL] [Abstract][Full Text] [Related]
3. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
[TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
Levine M; Moutquin JM; Walton R; Feightner J;
CMAJ; 2001 Jun; 164(12):1681-90. PubMed ID: 11450210
[TBL] [Abstract][Full Text] [Related]
6. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
Waters EA; McNeel TS; Stevens WM; Freedman AN
Breast Cancer Res Treat; 2012 Jul; 134(2):875-80. PubMed ID: 22622807
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
[TBL] [Abstract][Full Text] [Related]
8. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Tseng CW; Wong JB
JAMA; 2019 Sep; 322(9):857-867. PubMed ID: 31479144
[TBL] [Abstract][Full Text] [Related]
9. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
[TBL] [Abstract][Full Text] [Related]
10. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer prevention trials.
Rhodes DJ; Hartmann LC; Perez EA
Curr Oncol Rep; 2000 Nov; 2(6):558-65. PubMed ID: 11122893
[TBL] [Abstract][Full Text] [Related]
12. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
[TBL] [Abstract][Full Text] [Related]
13. The use of tamoxifen and raloxifene for the prevention of breast cancer.
Wickerham DL; Costantino JP; Vogel VG; Cronin WM; Cecchini RS; Ford LG; Wolmark N
Recent Results Cancer Res; 2009; 181():113-9. PubMed ID: 19213563
[TBL] [Abstract][Full Text] [Related]
14. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
Nelson HD; Smith ME; Griffin JC; Fu R
Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of breast cancer.
Brown PH; Lippman SM
Breast Cancer Res Treat; 2000 Jul; 62(1):1-17. PubMed ID: 10989982
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of breast cancer.
Thomsen A; Kolesar JM
Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention of breast cancer.
Dalton RR; Kallab AM
South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of antiestrogens for prevention of breast cancer.
Reddy P; Chow MS
Am J Health Syst Pharm; 2000 Jul; 57(14):1315-22; quiz 1323-5. PubMed ID: 10918921
[TBL] [Abstract][Full Text] [Related]
20. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
Dunn BK; Ford LG
Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
